BLSM BlossomHill Therapeutics, Inc.
$16.39▲ +12.03%
Healthcare
Other
Volume 204.4K
Avg Volume (10D) 137.2K
Key Metrics & Fundamentals
Market Cap
$520.95M
P/E Ratio
–
Div Yield
0.00%
52W Range
12.93 - 27.99
% vs 50 MA
-13.93%
% vs 200 MA
–%
RSI-14
46.3
MACD Histogram
-0.0200
Beta (1Y vs SPY)
1.11
Free Cash Flow
-$23.23M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$24.55M
COGS
–
Operating Exp
$24.67M
Operating Income
-$24.67M
EBIT
-$24.67M
Pretax Income
-$23.76M
Net Income
-$23.76M
EPS (Diluted)
-0.78
Price & Volume History
Loading chart…
Recent News
BlossomHill Therapeutics Announces Collaboration with Foundation Medicine to Develop First Companion Diagnostic for BH-30643 in EGFR C797S Mutated Non-Small Cell Lung Cancer
GlobeNewswire · Oct 22, 2026 7:00 AM ET
BlossomHill Therapeutics Presents Preclinical Data on Novel Pan-KRAS Inhibitor, BH-501284, at the AACR Conference on Pancreatic Cancer
GlobeNewswire · Sep 28, 2026 7:00 AM ET
BlossomHill Therapeutics Q2 Loss Widens
MT Newswires · Sep 18, 2026 7:42 AM ET
BlossomHill Therapeutics Reports Second Quarter 2026 Financial Results
GlobeNewswire · Sep 18, 2026 7:00 AM ET
BlossomHill Therapeutics Shares Rise 4.4% After BH-30643 Trial Update
InvestorsHub · Sep 15, 2026 10:13 AM ET
BlossomHill Drug Shows 45% Response Rate in Lung Cancer Trial
MT Newswires · Sep 15, 2026 7:42 AM ET
BlossomHill Therapeutics Presents Updated Data from Ongoing Phase 1/2 SOLARA Trial Demonstrating Encouraging Anti-Tumor Activity of OMNI-EGFR™ Inhibitor BH-30643 in EGFR C797S-Positive NSCLC at IASLC 2026 World Conference on Lung Cancer
GlobeNewswire · Sep 15, 2026 7:00 AM ET
BlossomHill Therapeutics to Present at the 8th Annual RAS-Targeted Drug Development Summit & H.C. Wainwright 28th Annual Global Investment Conference
GlobeNewswire · Sep 3, 2026 7:00 AM ET
BlossomHill Therapeutics to Present Updated Data from Ongoing Phase 1/2 SOLARA Trial of its Macrocyclic OMNI-EGFR™ Inhibitor, BH-30643, in EGFR-mutant NSCLC at the 2026 World Conference on Lung Cancer
GlobeNewswire · Sep 1, 2026 7:00 AM ET
Insiders Are Betting Big on These 3 Healthcare Stocks
MarketBeat · Aug 31, 2026 1:20 PM ET
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See BLSM's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.